Kodiak Sciences Inc. (KOD)
Company Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases.
Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD.
The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015.
Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
| Country | United States |
| IPO Date | Oct 4, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | Dr. Victor Perlroth M.D. |
Contact Details
Address: 1200 Page Mill Road Palo Alto, California United States | |
| Website | https://kodiak.com |
Stock Details
| Ticker Symbol | KOD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001468748 |
| CUSIP Number | 50015M109 |
| ISIN Number | US50015M1099 |
| Employer ID | 27-0476525 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Victor Perlroth M.D. | Co-Founder, Chairman, Chief Executive Officer & President |
| John A. Borgeson CPA, M.B.A. | Executive Vice President, Chief Financial Officer & Secretary |
| Almas Qudrat M.Sc. | Chief Quality Officer |
| Dr. Dolly S. Chang M.D., M.P.H., Ph.D. | Chief Scientific Officer |
| Dr. Hong Liang Ph.D. | Senior Vice President of Development |
| Dr. J. Pablo Velazquez-Martin M.D. | Chief Medical Officer |
| Dr. Laurent Ducay Ph.D. | Senior Vice President of Biologics Development & Manufacturing |
| Dr. Stephen Raillard Ph.D. | Senior Vice President of Chemical Development & Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 03, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| Apr 29, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 22, 2025 | ARS | Filing |
| Apr 22, 2025 | DEFA14A | Filing |
| Apr 22, 2025 | DEF 14A | Filing |
| Mar 27, 2025 | S-8 | Filing |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |